Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Injectable and implantable contraceptives.

V E Cullins1

  • 1Department of Obstetrics and Gynecology, Francis Scott Key Medical Center, Baltimore, MD 21224.

Current Opinion in Obstetrics & Gynecology
|August 1, 1992
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Partner effects on a woman's intention to conceive: 'not with this partner'.

Family planning perspectives·2000
Same author

Implantable hormonal and emergency contraception.

Current opinion in obstetrics & gynecology·1997
Same author

Noncontraceptive benefits and therapeutic uses of depot medroxyprogesterone acetate.

The Journal of reproductive medicine·1996
Same author

Contraceptive outcomes among post-partum and post-abortal adolescents.

Contraception·1994
Same author

Comparison of adolescent and adult experiences with Norplant levonorgestrel contraceptive implants.

Obstetrics and gynecology·1994
Same author

Subdermal contraceptive implants in nurse-midwifery practice.

Journal of nurse-midwifery·1993

Norplant, a reversible contraceptive implant, was approved in 1990. Studies show it does not act as an abortifacient and has clinically insignificant metabolic effects, offering diverse contraceptive options.

Area of Science:

  • Reproductive Health
  • Contraception
  • Endocrinology

Background:

  • The Food and Drug Administration approved Norplant for general US use in December 1990.
  • Rising rates of sterilization reflect dissatisfaction with existing reversible contraceptive methods.
  • Concerns regarding Norplant's potential abortifacient properties have been addressed by recent data.

Purpose of the Study:

  • To evaluate the safety and efficacy of Norplant as a reversible contraceptive.
  • To investigate Norplant's impact on ovulation and hormonal profiles.
  • To assess metabolic changes associated with Norplant use.

Main Methods:

  • Documentation of estradiol production, follicle development, and ovulation in regularly menstruating women using Norplant.
Keywords:
AmericasBehaviorContraceptionContraception ContinuationContraceptive AgentsContraceptive Agents, FemaleContraceptive Agents, ProgestinContraceptive ImplantsContraceptive MethodsContraceptive UsageDepo-proveraDeveloped CountriesDrug InteractionsDrugsEconomic FactorsFamily PlanningInjectablesLevonorgestrelLiterature ReviewMedroxyprogesterone AcetateNorethindroneNorethindrone EnanthateNorth AmericaNorthern AmericaPsychological FactorsResearch And DevelopmentSatisfactionTechnologyTreatmentUnited States

Related Experiment Videos

  • Detailed analysis of ovulatory dysfunction in Norplant users.
  • Confirmation of clinically insignificant changes in carbohydrate metabolism.

    • Main Results:

    • Norplant use was associated with continued estradiol production, follicle development, and ovulation in regularly menstruating women.
    • Ovulatory dysfunction was observed in some Norplant users, despite follicular development.
    • Metabolic changes, specifically in carbohydrate metabolism, were found to be clinically insignificant.

    Conclusions:

    • Norplant is a safe and effective reversible contraceptive option, refuting concerns about its abortifacient potential.
    • Norplant use can lead to ovulatory dysfunction, indicating a need for further research.
    • Ongoing international development of various implantable and injectable contraceptives promises expanded choices for diverse contraceptive needs.